Comment on Timmers et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016;39:2211–2217

The recent study by Timmers et al. (1) is a valuable randomized, double-blind, crossover clinical trial involving patients with well-controlled type 2 diabetes who were assigned to receive placebo and 150 mg/day resveratrol for 30 days to evaluate insulin sensitivity via hyperinsulinemic-euglycemic clamp. After the intervention, the authors found that hepatic and peripheral insulin sensitivity were not affected by the resveratrol treatment, and additionally, no significant changes in intrahepatic lipid content were found. However, the authors found an increase in intramyocellular lipid content in type 2 muscle fibers, a tendency for blood pressure to decrease, and an improvement of ex vivo mitochondrial function. The authors concluded …